21:31 , Dec 19, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with p53 knocked out, ATRX knocked down and both PDGFRA and K27M-mutant H3.3A overexpressed could be useful for screening therapies to treat pediatric high-grade gliomas. In mice, embryos engineered in utero...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer; neuroendocrine tumors Multiple endocrine neoplasia I (MEN1; menin); death-domain associated protein...
08:00 , Nov 18, 2010 |  BC Innovations  |  Targets & Mechanisms

GABAA: better late

The vast majority of ischemic stroke patients are unable to receive treatment with tissue plasminogen activator (tPA) within the drug's three-hour efficacy window, and there are no approved therapies that promote recovery of motor function...
07:00 , Sep 11, 2006 |  BioCentury  |  Strategy

MediGene chronicles

MediGene chronicles MediGene chroniclesSelected events tracked against MediGene’s weekly stock price (FSE:MDG). Y-axis = logarithmic scale A. 6/30/00 - Raises E125.4M ($117.4M) in an IPO. At that time, MDG was focused on developing therapeutics for cardiovascular...
08:00 , Nov 22, 2004 |  BC Week In Review  |  Company News

Atrix, QLT deal

QLT completed its previously announced acquisition of ATRX for one QLT share plus $14.61 in cash for every ATRX share held (see BioCentury, June 21). Using QLTI's Nov. 19 close of $15.42 and ATRX's 21.4...
08:00 , Nov 19, 2004 |  BC Extra  |  Top Story

QLT buys Atrix

QLT (TSE:QLT; QLTI) completed its previously announced acquisition of ATRX for one QLT share plus $14.61 in cash for every ATRX share held (see BioCentury Extra, Monday June 14, 2004). Using QLTI's Friday...
08:00 , Nov 15, 2004 |  BioCentury  |  Finance

Ebb & Flow

Although November is only half over, more money has been raised in follow-ons this month than in the previous three months combined: $512.4 million compared with $216.8 million from August through October. OSIP did the...
07:00 , Oct 4, 2004 |  BioCentury  |  Product Development

No pain AND no gain

People who need to lose weight want to do so without feeling like they are constantly hungry. Nastech Inc. says that its intranasal version of the natural hormone PYY3-36 induces a feeling of satiety in...
07:00 , Sep 6, 2004 |  BC Week In Review  |  Clinical News

Aczone regulatory update

The partners submitted an NDA for Aczone 5% dapsone gel to treat acne. ATRX is being acquired by QLT Inc. (TSE:QLT; QLTI, Vancouver, B.C.) (see BioCentury, June 21). Atrix Laboratories Inc. (ATRX), Fort Collins,...